Epigenetic modulators of these chemokine receptors relieved the suppression of these Th1-cell-type chemokines and increased TILs leading to improved therapeutic efficacy of PD-L1 inhibitor in a model for ovarian cancer (155). This evidence concerns the gene CD274 and ovarian carcinoma.